SCHEMBL3527898

SCHEMBL3527898

COC(=O)c1cc(Cl)cc(NS(=O)(=O)C(F)(F)F)c1Cl

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PDK2 Q15119 3/20 0.44
▸ EPAS1 Q99814 1/20 0.41
▸ CA2 P00918 3/20 0.40
▸ CA1 P00915 2/20 0.40
▸ PDK1 Q15118 1/20 0.40
▸ PDK3 Q15120 1/20 0.40
▸ PDK4 Q16654 1/20 0.40
▸ ACLY P53396 3/20 0.39
▸ SERPINH1 P50454 1/20 0.37
▸ ABL1 P00519 1/20 0.37
▸ PTGS1 P23219 3/20 0.37
▸ PTGS2 P35354 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ SLC22A12 Q96S37 1/20 0.36
▸ MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13544287 0.84 ACLY (0.44) CA2CA1ACLYPTGS1PTGS2
SCHEMBL13719782 0.83 CA2 (0.43) CA2CA1ACLYPTGS1PTGS2
SCHEMBL27241 0.83 ABL1 (0.47) CA2ACLYABL1PTGS1PTGS2
Hydrochloric Acid SCHEMBL3527460 0.83 ACLY (0.43) CA2CA1ACLYPTGS1PTGS2
SCHEMBL3527061 0.82 KDM4E (0.54) PDK2ACLYSERPINH1ABL1SMN1; SMN2
SCHEMBL13747717 0.82 CA2 (0.39) PDK2CA2CA1ACLYPTGS1
SCHEMBL3530056 0.80 GAA (0.44) EPAS1CA2CA1ACLYPTGS1
SCHEMBL31518457 0.74 TSHR (0.57) CA2CA1KDM4EHSD17B10MAPK1
SCHEMBL3738491 0.72 CFTR (0.54) CA2CA1SMN1; SMN2KDM4EHSD17B10
SCHEMBL21111046 0.72 CFTR (0.57) CA2ACLYSMN1; SMN2KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 — — US disclosed
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 — — US disclosed
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 — — US disclosed
US-20060229336-A1 Ccr5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORPORATION 2006-10-12 — — US disclosed
EP-1569646-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-07 — — EP disclosed
WO-2004054974-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229336-A1 Ccr5 antagonists as therapeutic agents CCR5, CCR1, CXCR3 PDK2 2053/4885EPAS1 747/4885CA2 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback